Invivyd (IVVD) Capital Expenditures Growth (1y) (2022 - 2025)
Invivyd (IVVD) Capital Expenditures Growth (1y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 143.40% |
| 10 | Invivyd | 105.12 Mn | -121.57 Mn | 16.07 Mn | 3,760.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,760.00% |
| Sep 30, 2025 | 99.32% |
| Jun 30, 2025 | 89.47% |
| Mar 31, 2025 | -100.59% |
| Dec 31, 2024 | 58.33% |
| Sep 30, 2024 | -1,304.81% |
| Mar 31, 2024 | 1,582.00% |
| Dec 31, 2023 | -100.25% |
| Sep 30, 2023 | -65.08% |
| Mar 31, 2023 | 103.27% |
| Dec 31, 2022 | 44.56% |